Name: Generation of 3D Whole Lung Organoids from Induced Pluripotent Stem Cells for Modeling Lung Developmental Biology and Disease (Video) | JoVE Journal
Uploaded: 2021-04-12T15:00:00.000+00:00
Duration: 9 min 45 s
Description: Learn to generate 3D lung organoids from hiPSCs using stepwise differentiation and matrix embedding techniques. This method enables modeling of human lung development and disease in vitro.

ai_agent_IP

ai_agent

maintenance

instantTrialDurationMinutes

isBiopharma

enableNewMyJoveSectionDesign

educationFeatures

seoMetaApi

ai_copilot_institution_blacklist

ai_chat_institution_blacklist

freeAccessWindow

ssoRoleCapture

scheduledMaintenanceBanner

joveLabsFeatures

disable_autoplay_for_bots

extended_trial_duration

5 minutes

This research was supported by the California Institute for Regenerative Medicine (CIRM)&#160;&#160;(DISC2-COVID19-12022).

This study protocol was approved by the Institutional Review Board of UCSD&#39;s Human Research Protections Program (181180).
1. Definitive endoderm induction from induced pluripotent stem cells (Day 1 - 3)
<ol>
	<li>Slowly thaw growth factor reduced (GFR)-basement membrane (BM) matrix medium on ice 30 minutes prior to use. In cold DMEM/F12, mixture, dilute the GFR BM matrix medium 1:1 such that it constitutes 50% of this medium. Place P1000 pipette tips in the freezer to chill prior to use.</li>
	<li>Coat each well of a 12-well plate with 500 &#181;L of 50% GFR-basement membrane matrix medium prepared in ice-cold DMEM/F12. Once the desired number of wells are coated, remove any excess medium mixture and/or bubbles from wells and place the plate on ice or refrigerator at 4 &#176;C for 20 min to set. Then, move the plate to the incubator at 37 &#176;C overnight to gel and dry.</li>
	<li>Once hiPSCs reach 70-90% confluency, add 10 &#181;M of Rho-associated kinase (ROCK)&#160;Inhibitor Y-27632 an hour prior to dissociation. Aspirate off the media and wash once with Phosphate buffered saline (PBS). Dissociate hiPSCs by adding cell detachment medium (0.5 mL/ well of a 12-well plate) and incubate for 20 min at 37 &#176;C in a 5% CO2 incubator.</li>
	<li>Remove plates from the incubator and add 0.5 mL/12-well of stem cell passaging medium (Table 1) to the wells; gently triturate&#160;cells using a P1000 tip to obtain single-cell suspension. Transfer dissociated cells into a 15 mL conical centrifuge tube; centrifuge for 5 min at 300 x g.</li>
	<li>Aspirate off the medium and resuspend the cell pellet with 1 mL of mTeSR Plus media supplemented with 10 &#181;M ROCK inhibitor (Y-27632). Perform a cell count. Add 2.0 x 105&#160;hiPSCs in 1 mL of mTeSR supplemented with ROCK Inhibitor Y-27632 per well of a 12-well GFR-basement membrane medium coated plate. Incubate at 37 &#176;C overnight. 
	NOTE: Cell seeding number must be optimized per cell line. 24 h after plating, wells should be 50%-70% confluent.</li>
	<li>On day 1, aspirate off the mTeSR Plus and add Definitive Endoderm (DE) induction media (Table 1) supplemented with 100 ng/mL of human activin A and 5 &#181;M of GSK3&#946; inhibitor/Wnt activator CHIR99021. 
	&#8203;NOTE: DE media with GSK3&#946; inhibitor/Wnt activator CHIR99021 should be removed within 20-24 h of day 1 DE induction for successful differentiation.</li>
	<li>On day 2 and day 3, change to DE induction media supplemented with 100 ng/mL of activin A only. 
	&#8203;NOTE: DE differentiation should not exceed a total of 72 h, or efficacy will decrease. On day 4, if large cell die-off is observed, decrease total DE media exposure time by 6-12 h.</li>
	<li>To analyze DE efficiency, confirm greater than 90% CXCR4 and/or cKit expression via flow cytometry or immunofluorescence analysis of FOXA2 and/or SOX17 (Figure 2a).</li>
</ol>
2. Anterior foregut endoderm (AFE) induction (Day 4 - 6)
<ol>
	<li>On day 4, change media to serum free basal medium (SFBM) (Table 1) supplemented with 10 &#181;M SB431542 and 2 &#181;M Dorsomorphin for AFE induction. Change AFE media daily for 3 days (day 4, day 5, and day 6).</li>
	<li>To analyze AFE efficiency, confirm robust expression of SOX2, TBX1, and FOXA2 via immunofluorescence staining (Figure 2b).</li>
</ol>
3. Lung progenitor cell (LPC) differentiation (Day 7 - 16)
<ol>
	<li>On day 7, thaw GFR-basement membrane matrix medium on ice. Aspirate off the AFE media and wash well with 1x PBS. Add 1 mL of cell detachment solution and incubate for 10 min at 37 &#176;C.</li>
	<li>Add 1 mL of quenching medium (2% FBS in DMEM/F12) to the wells containing cell detachment solution. Keep cells as aggregates by pipetting up and down gently. Make sure all cells are dislodged and transferred into a 15 mL conical centrifuge tube. Centrifuge for 5 min at 300 x g.</li>
	<li>Remove the supernatant and resuspend the cell pellet in Quenching medium&#160;supplemented with 10 ng/mL of human recombinant bone morphogenic protein-4 (BMP4), 0.1 &#181;M of all-trans retinoic acid (RA), 3 &#181;M of GSK3&#946; inhibitor/Wnt activator CHIR99021, and 10 &#181;M of Rock Inhibitor Y-27632.</li>
	<li>Perform a cell count. Add 2.5 x 105 cells to 100 &#181;L of cold GFR-basement membrane matrix medium, mix well, and place droplet into a well of a 12-well plate. Incubate the plate at 37 &#176;C for 30-60 min to allow the medium to polymerize. Add 1 mL of LPC media supplemented with 10 &#181;M of ROCK Inhibitor Y-27632 per well ensuring the medium drop is fully submerged and incubate at 37 &#176;C overnight.</li>
	<li>On day 8, 24 h after LPC induction, change LPC medium to remove ROCK Inhibitor Y-27632. Change the LPC medium every other day for a total of 9-11 days. 
	NOTE: If the medium becomes yellow within 24 h, change medium every day.</li>
	<li>To analyze LPC efficiency, confirm robust expression of the intracellular transcription factor NKX2-1 or perform flow cytometry for surface markers CD47hi/CD26low15 or CPM18 (Figure 2c). Grossly, the LPC spheroids should be round and transparent (Figure 2c). 
	&#8203;NOTE: Do not proceed with lung organoid differentiation if efficiency of NKX2-1 is below 30%.</li>
</ol>
4. 3D lung organoid induction (Day 16 - 22)
<ol>
	<li>On day 17, thaw GFR-basement membrane matrix medium on ice. Aspirate the LPC induction medium. Then add 2 &#181;g/mL of dispase (1&#160;mL) to the well and resuspend the medium/dispase mixture with a P1000 pipette. Incubate at&#160;37 &#176;C for 15 min. Triturate the mixture again and incubate at&#160;37 &#176;C for another 15 min.</li>
	<li>Transfer the dispase and cells into a 15 mL conical centrifuge tube. Use chilled PBS (2-3 mL) to wash the well and resuspend the dispase/cell mixture. Centrifuge for 5 min at 400 x g. Manually remove the supernatant, being careful not to distub the medium/cell pellet layer. Repeat the chilled PBS wash, and&#160;centrifuge the conical centrifuge tube for another 5 min at 400 x g.</li>
	<li>Manually remove the supernatant, and then add 2 mL of trypsin- based dissociation solution to the conical centrifuge tube. Incubate at 37 &#176;C for 12 min.</li>
	<li>After incubation, resuspend cells with a P1000 pipette tip. Then add an equal volume of quenching media to the conical centrifuge tube and spin down at 400 x g for 5 min. Aspirate the supernatant and resuspend cells&#160; in quenching medium + 10 &#181;M of ROCK Inhibitor Y-27632. 
	NOTE: Successful lung organoid induction occurs when cells are embedded as aggregates, not single cells, adjust pipetting accordingly.</li>
	<li>Perform a cell count. Calculate the volume needed to obtain 5.0-8.0 x 104 cells per well. Aliquot the LPC cell aggregates into 1.5 mL microcentrifuge tubes and centrifuge for 5 min at 400 x g. Remove excess supernatant, being careful to not agitate the cell pellet. Leave only 10 &#181;L of residual media.</li>
	<li>Re-suspend the cell pellet in 200 &#181;L of cold GFR-basement membrane matrix medium and add to cell culture membrane inserts (6.5 mm diameter, 0.4 &#181;m pore, polyester membrane). Incubate the plate at 37 &#176;C for 30-60 min to allow GFR-basement membrane matrix medium to polymerize.</li>
	<li>Add 1 mL of 3D organoid induction medium (Table 1) supplemented with&#160;fibroblast growth factor-7&#160;(FGF7) (10 ng/mL), FGF10 (10 ng/mL), GSK3&#946; inhibitor/Wnt activator CHIR (3 &#181;M), epidermal growth factor (EGF) (10 ng/mL), and 10 &#181;M of ROCK&#160;Inhibitor Y-27632 to the basolateral chamber of the membrane insert. Change the medium every other day for 6 days.</li>
</ol>
5. 3D Lung organoid branching (Day 23 - 28)
<ol>
	<li>On day 23 change to 3D branching medium (Table 1) supplemented with FGF7 (10 ng/mL), FGF10 (10 ng/mL), GSK3&#946; inhibitor/Wnt activator CHIR99021 (3 &#181;M), RA (0.1 &#181;M), EGF (10 ng/mL), and vascular endothelial growth factor (VEGF) / placental growth factor (PlGF)&#160;(10 ng/mL). Change the medium every other day for 6 days. 
	NOTE: At day 6 of 3D branching differentiation, there should be multiple branching organoids (Figure 2).</li>
</ol>
6. 3D lung organoid maturation (Day 29 - 34)
<ol>
	<li>On day 29, change to 3D maturation medium (Table 1), which is the same as 3D branching medium but with the addition of dexamethasone (50 nM), cAMP (100 &#181;M), and and 3-isobutyl-1-methylxanthine (IBMX), a phosphodiesterase inhibitor also termed isobutylxanthine&#160;(100 &#181;M). Change the medium every other day for 6 days. 
	&#8203;NOTE: Within 24 h after 3D maturation, the branching organoids should expand and change into transparent spheres.</li>
</ol>
7. 3D Lung organoid immunocytochemistry
<ol>
	<li>For 3D whole lung organoid analysis, fix GFR-basement membrane matrix medium in the membrane inserts with 4% paraformaldehyde (PFA) for 1 h at 4 &#176;C. Embed in paraffin wax and mount onto slides per standard published protocols.</li>
	<li>Perform antigen retrieval prior to staining. Airway markers include KRT5, MUC5AC, and SCGB3A2. Alveolar markers include SP-C, SP-B, HTII-280, HTI-56, and HOPX (Figure 3).</li>
</ol>
8. Removal of whole lung organoids from GFR-basement membrane matrix medium for passage, FACS, or cryopreservation
<ol>
	<li>To dissociate the organoids from the GFR-basement membrane matrix medium, remove media from the basal chamber and add 2 &#181;g/mL of dispase (1 mL) in the apical chamber.</li>
	<li>Gently triturate the medium /dispase mixture with a P1000 pipette and place in the incubator for 15 min. Gently triturate the mixture again and incubate for another 15 min.</li>
	<li>Add 1 mL of chilled PBS (4 &#176;C) and transfer organoids with the matrix medium into a 15 mL conical centrifuge tube. Spin at 400 x g for 5 min. Remove the supernatant carefully, not to disturb the cell pellet.</li>
	<li>Wash once more with 1 mL chilled PBS and spin down at 400 x g for 5 min. Remove the supernatant carefully, not to disturb the medium/cell mixture.</li>
	<li>Add 1 mL of cell detachment solution to the conical centrifuge tube, gently triturate resuspend the GFR-Basement membrane matrix medium/cell mixture. Place in the incubator for 12 min for passaging cells as aggregates or for cryopreservation), or 20 min for single cell suspension.</li>
	<li>Add equal volume of quenching media and spin down at 400 x g for 5 min. Resuspend in quenching medium + 10 &#181;M of ROCK Inhibitor Y-27632. 
	NOTE: At this step, no residual basement membrane medium should be seen in the tube. If residual medium remains, repeat steps 8.5 and 8.6.</li>
	<li>Perform a cell count. Calculate the volume needed for downstream applications.</li>
</ol>

<ol><li>Ten Have-Opbroek, A. A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Lung+development+in+the+mouse+embryo%5BTitle%5D)+AND+%22Experimental+Lung+Research%22%5BJournal%5D)">Lung development in the mouse embryo.</a> Experimental Lung Research. 17 (2), 111-130 (1991).</li>
<li>Perl, A. K., Whitsett, J. A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Molecular+mechanisms+controlling+lung+morphogenesis%5BTitle%5D)+AND+%22Clinical+Genetics%22%5BJournal%5D)">Molecular mechanisms controlling lung morphogenesis.</a> Clinical Genetics. 56 (1), 14-27 (1999).</li>
<li>Leibel, S., Post, M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Endogenous+and+exogenous+stem%2Fprogenitor+cells+in+the+lung+and+their+role+in+the+pathogenesis+and+treatment+of+pediatric+lung+disease%5BTitle%5D)+AND+%22Frontiers+in+Pediatrics%22%5BJournal%5D)">Endogenous and exogenous stem/progenitor cells in the lung and their role in the pathogenesis and treatment of pediatric lung disease.</a> Frontiers in Pediatrics. 4, 36(2016).</li>
<li>Hines, E. A., Sun, X. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Tissue+crosstalk+in+lung+development%5BTitle%5D)+AND+%22Journal+of+Cellular+Biochemistry%22%5BJournal%5D)">Tissue crosstalk in lung development.</a> Journal of Cellular Biochemistry. 115 (9), 1469-1477 (2014).</li>
<li>Montoro, D. T., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((A+revised+airway+epithelial+hierarchy+includes+CFTR-expressing+ionocytes%5BTitle%5D)+AND+%22Nature%22%5BJournal%5D)">A revised airway epithelial hierarchy includes CFTR-expressing ionocytes.</a> Nature. 560 (7718), 319-324 (2018).</li>
<li>Barkauskas, C. E., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Type+2+alveolar+cells+are+stem+cells+in+adult+lung%5BTitle%5D)+AND+%22The+Journal+of+Clinical+Investigation%22%5BJournal%5D)">Type 2 alveolar cells are stem cells in adult lung.</a> The Journal of Clinical Investigation. 123 (7), 3025-3036 (2013).</li>
<li>D'Amour, K. A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Efficient+differentiation+of+human+embryonic+stem+cells+to+definitive+endoderm%5BTitle%5D)+AND+%22Nature+Biotechnology%22%5BJournal%5D)">Efficient differentiation of human embryonic stem cells to definitive endoderm.</a> Nature Biotechnology. 23 (12), 1534-1541 (2005).</li>
<li>Green, M. D., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Generation+of+anterior+foregut+endoderm+from+human+embryonic+and+induced+pluripotent+stem+cells%5BTitle%5D)+AND+%22Nature+Biotechnology%22%5BJournal%5D)">Generation of anterior foregut endoderm from human embryonic and induced pluripotent stem cells.</a> Nature Biotechnology. 29 (3), 267-272 (2011).</li>
<li>Ikeda, K., Shaw-White, J. R., Wert, S. E., Whitsett, J. A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Hepatocyte+nuclear+factor+3+activates+transcription+of+thyroid+transcription+factor+1+in+respiratory+epithelial+cells%5BTitle%5D)+AND+%22Molecular+Cell+Biology%22%5BJournal%5D)">Hepatocyte nuclear factor 3 activates transcription of thyroid transcription factor 1 in respiratory epithelial cells.</a> Molecular Cell Biology. 16 (7), 3626-3636 (1996).</li>
<li>Schittny, J. C. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Development+of+the+lung%5BTitle%5D)+AND+%22Cell+and+Tissue+Research%22%5BJournal%5D)">Development of the lung.</a> Cell and Tissue Research. 367 (3), 427-444 (2017).</li>
<li>Mecham, R. P. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Elastin+in+lung+development+and+disease+pathogenesis%5BTitle%5D)+AND+%22Matrix+Biology%3A+Journal+of+the+International+Society+for+Matrix+Biology%22%5BJournal%5D)">Elastin in lung development and disease pathogenesis.</a> Matrix Biology: Journal of the International Society for Matrix Biology. 73, 6-20 (2018).</li>
<li>Bellusci, S., Grindley, J., Emoto, H., Itoh, N., Hogan, B. L. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Fibroblast+growth+factor+10+%28FGF10%29+and+branching+morphogenesis+in+the+embryonic+mouse+lung%5BTitle%5D)+AND+%22Development%22%5BJournal%5D)">Fibroblast growth factor 10 (FGF10) and branching morphogenesis in the embryonic mouse lung.</a> Development. 124 (23), 4867-4878 (1997).</li>
<li>Bellusci, S., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Involvement+of+Sonic+hedgehog+%28Shh%29+in+mouse+embryonic+lung+growth+and+morphogenesis%5BTitle%5D)+AND+%22Development%22%5BJournal%5D)">Involvement of Sonic hedgehog (Shh) in mouse embryonic lung growth and morphogenesis.</a> Development. 124 (1), 53-63 (1997).</li>
<li>Yamamoto, Y., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Long-term+expansion+of+alveolar+stem+cells+derived+from+human+iPS+cells+in+organoids%5BTitle%5D)+AND+%22Nature+Methods%22%5BJournal%5D)">Long-term expansion of alveolar stem cells derived from human iPS cells in organoids.</a> Nature Methods. 14 (11), 1097-1106 (2017).</li>
<li>Hawkins, F., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Prospective+isolation+of+NKX2-1-expressing+human+lung+progenitors+derived+from+pluripotent+stem+cells%5BTitle%5D)+AND+%22The+Journal+of+Clinical+Investigation%22%5BJournal%5D)">Prospective isolation of NKX2-1-expressing human lung progenitors derived from pluripotent stem cells.</a> The Journal of Clinical Investigation. 127 (6), 2277-2294 (2017).</li>
<li>McCauley, K. B., Hawkins, F., Kotton, D. N. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Derivation+of+epithelial-only+airway+organoids+from+human+pluripotent+stem+cells%5BTitle%5D)+AND+%22Current+Protocols+in+Stem+Cell+Biology%22%5BJournal%5D)">Derivation of epithelial-only airway organoids from human pluripotent stem cells.</a> Current Protocols in Stem Cell Biology. 45 (1), 51(2018).</li>
<li>Miller, A. J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Generation+of+lung+organoids+from+human+pluripotent+stem+cells+in+vitro%5BTitle%5D)+AND+%22Nature+Protocols%22%5BJournal%5D)">Generation of lung organoids from human pluripotent stem cells in vitro.</a> Nature Protocols. 14 (2), 518-540 (2019).</li>
<li>Gotoh, S., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Generation+of+alveolar+epithelial+spheroids+via+isolated+progenitor+cells+from+human+pluripotent+stem+cells%5BTitle%5D)+AND+%22Stem+Cell+Reports%22%5BJournal%5D)">Generation of alveolar epithelial spheroids via isolated progenitor cells from human pluripotent stem cells.</a> Stem Cell Reports. 3 (3), 394-403 (2014).</li>
<li>Huang, S. X., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Efficient+generation+of+lung+and+airway+epithelial+cells+from+human+pluripotent+stem+cells%5BTitle%5D)+AND+%22Nature+Biotechnology%22%5BJournal%5D)">Efficient generation of lung and airway epithelial cells from human pluripotent stem cells.</a> Nature Biotechnology. 32 (1), 84-91 (2014).</li>
<li>Endale, M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Temporal%2C+spatial%2C+and+phenotypical+changes+of+PDGFR%CE%B1+expressing+fibroblasts+during+late+lung+development%5BTitle%5D)+AND+%22Developmental+Biology%22%5BJournal%5D)">Temporal, spatial, and phenotypical changes of PDGFRα expressing fibroblasts during late lung development.</a> Developmental Biology. 425 (2), 161-175 (2017).</li>
<li>Fatehullah, A., Tan, S. H., Barker, N. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Organoids+as+an+in+vitro+model+of+human+development+and+disease%5BTitle%5D)+AND+%22Nature+Cell+Biology%22%5BJournal%5D)">Organoids as an in vitro model of human development and disease.</a> Nature Cell Biology. 18 (3), 246-254 (2016).</li>
<li>Nikolić, M. Z., Rawlins, E. L. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Lung+organoids+and+their+use+to+study+cell-cell+interaction%5BTitle%5D)+AND+%22Current+Pathobiology+Reports%22%5BJournal%5D)">Lung organoids and their use to study cell-cell interaction.</a> Current Pathobiology Reports. 5 (2), 223-231 (2017).</li>
<li>Calvert, B. A., Ryan Firth, A. L. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Application+of+iPSC+to+modelling+of+respiratory+diseases%5BTitle%5D)+AND+%22Advances+on+Experimental+Medicine+and+Biology%22%5BJournal%5D)">Application of iPSC to modelling of respiratory diseases.</a> Advances on Experimental Medicine and Biology. 1237, 1-16 (2020).</li>
<li>McCulley, D., Wienhold, M., Sun, X. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((The+pulmonary+mesenchyme+directs+lung+development%5BTitle%5D)+AND+%22Current+Opinion+in+Genetics+and+Development%22%5BJournal%5D)">The pulmonary mesenchyme directs lung development.</a> Current Opinion in Genetics and Development. 32, 98-105 (2015).</li>
<li>Blume, C., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Cellular+crosstalk+between+airway+epithelial+and+endothelial+cells+regulates+barrier+functions+during+exposure+to+double-stranded+RNA%5BTitle%5D)+AND+%22Immunity%2C+Inflammation+and+Disease%22%5BJournal%5D)">Cellular crosstalk between airway epithelial and endothelial cells regulates barrier functions during exposure to double-stranded RNA.</a> Immunity, Inflammation and Disease. 5 (1), 45-56 (2017).</li>
<li>Leibel, S. L., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Reversal+of+surfactant+protein+B+deficiency+in+patient+specific+human+induced+pluripotent+stem+cell+derived+lung+organoids+by+gene+therapy%5BTitle%5D)+AND+%22Scientific+Reports%22%5BJournal%5D)">Reversal of surfactant protein B deficiency in patient specific human induced pluripotent stem cell derived lung organoids by gene therapy.</a> Scientific Reports. 9 (1), 13450(2019).</li>
<li>Rock, J. R., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Basal+cells+as+stem+cells+of+the+mouse+trachea+and+human+airway+epithelium%5BTitle%5D)+AND+%22Proceedings+of+the+National+Academy+of+Sciences+of+the+United+States+of+America%22%5BJournal%5D)">Basal cells as stem cells of the mouse trachea and human airway epithelium.</a> Proceedings of the National Academy of Sciences of the United States of America. 106 (31), 12771-12775 (2009).</li>
<li>Gonzalez, R. F., Allen, L., Gonzales, L., Ballard, P. L., Dobbs, L. G. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((HTII-280%2C+a+biomarker+specific+to+the+apical+plasma+membrane+of+human+lung+alveolar+type+II+cells%5BTitle%5D)+AND+%22The+Journal+of+Histochemistry+and+Cytochemistry%3A+Official+Journal+of+the+Histochemistry+Society%22%5BJournal%5D)">HTII-280, a biomarker specific to the apical plasma membrane of human lung alveolar type II cells.</a> The Journal of Histochemistry and Cytochemistry: Official Journal of the Histochemistry Society. 58 (10), 891-901 (2010).</li>
<li>McCauley, K. B., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Single-cell+transcriptomic+profiling+of+pluripotent+stem+cell-derived+SCGB3A2%2B+airway+epithelium%5BTitle%5D)+AND+%22Stem+Cell+Reports%22%5BJournal%5D)">Single-cell transcriptomic profiling of pluripotent stem cell-derived SCGB3A2+ airway epithelium.</a> Stem Cell Reports. 10 (5), 1579-1595 (2018).</li>
<li>Sekine, K., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Robust+detection+of+undifferentiated+iPSC+among+differentiated+cells%5BTitle%5D)+AND+%22Scientific+Reports%22%5BJournal%5D)">Robust detection of undifferentiated iPSC among differentiated cells.</a> Scientific Reports. 10 (1), 10293(2020).</li>
<li>Jacquet, L., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Strategy+for+the+creation+of+clinical+grade+hESC+line+banks+that+HLA-match+a+target+population%5BTitle%5D)+AND+%22EMBO+Molecular+Medicine%22%5BJournal%5D)">Strategy for the creation of clinical grade hESC line banks that HLA-match a target population.</a> EMBO Molecular Medicine. 5 (1), 10-17 (2013).</li>
<li>Mattapally, S., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Human+leukocyte+antigen+class+I+and+II+knockout+human+induced+pluripotent+stem+cell-derived+cells%3A+universal+donor+for+cell+therapy%5BTitle%5D)+AND+%22Journal+of+the+American+Heart+Association%22%5BJournal%5D)">Human leukocyte antigen class I and II knockout human induced pluripotent stem cell-derived cells: universal donor for cell therapy.</a> Journal of the American Heart Association. 7 (23), 010239(2018).</li>
</ol>

The authors have nothing to disclose.

The successful differentiation of 3D whole lung organoids (WLO) relies on a multi-step, 6-week protocol with attention to detail, including time of exposure to growth factors and small molecules, cellular density after passaging, and the quality of hiPSCs. For troubleshooting, see Table 2. hiPSCs should be approximately 70%-80% confluent, with less than 5% spontaneous differentiation prior to dissociation. This protocol calls for &#34;mTeSR plus&#34; medium; however,&#160; plain &#34;mTeSR&#34; medium&#1...

The lung is a complicated, heterogeneous, dynamic organ that develops in six distinct stages - embryonic, pseudoglandular, canalicular, saccular, alveolar, and microvascular maturation1,2. The latter two phases occur pre and postnatally in human development while the first four stages occur exclusively during fetal development unless preterm birth occurs3. The embryonic phase begins in the endodermal germ layer and concludes with the budding of the trachea and lung buds. Lung development occurs in part via signaling between the epithelial and mesenchymal cells4. These interactions result in lung branching, proliferation, cellular fate determination and cellular differentiation of the developing lung. The lung is divided into conducting zones (trachea to the terminal bronchioles) and respiratory zones (respiratory bronchioles to the alveoli). Each zone contains unique epithelial cell types; including basal, secretory, ciliated, brush, neuroendocrine, and ionocyte cells in the conducting airway5, followed by alveolar type I and II cells in the respiratory epithelium6. Much is still unknown about the development and response to injury of the various cell types. iPSC derived lung organoid models enable the study of mechanisms that drive human lung development, the effects of genetic mutations on pulmonary function, and the response of both the epithelium and mesenchyme to infectious agents without the need for primary human lung tissue.
Markers corresponding to the various stages of embryonic differentiation include CXCR4, cKit, FOXA2, and SOX17 for definitive endoderm (DE)7, FOXA2, TBX1, and SOX2 for anterior foregut endoderm (AFE)8, and NKX2-1 for early lung progenitor cells9. In embryonic lung development, the foregut divides into the dorsal esophagus and ventral trachea. The buds of the right and left lungs appear as two independent outpouchings around the tracheal bud10. During branching morphogenesis, the mesenchyme surrounding the epithelium produces elastic tissue, smooth muscle, cartilage, and vasculature11. The interaction between the epithelium and mesenchyme is essential for normal lung development. This includes the secretion of FGF1012 by the mesenchyme and SHH13 produced by the epithelium.
Here, we describe a protocol for the directed differentiation of hiPSCs into three-dimensional (3D) whole lung organoids (WLO). While there are similar approaches that incorporate isolation of lung progenitor cells via sorting at the LPC stage to make alveolar-like14,15 (distal) organoids or airway16 (proximal) organoids, or generate ventral-anterior foregut spheroids to make human lung organoids expressing alveolar-cell and mesenchymal markers and bud tip progenitor organoids17, the strength of this method is the inclusion of both lung epithelial and mesenchymal cell types to pattern and orchestrate lung branching morphogenesis, maturation, and expansion in vitro.
This protocol uses small molecules and growth factors to direct the differentiation of pluripotent stem cells through definitive endoderm, anterior foregut endoderm, and lung progenitor cells. These cells are then induced into 3D whole lung organoids through important developmental steps, including branching and maturation. The summary of the differentiation protocol is shown in Figure 1a with representative brightfield images of endodermal and organoid differentiation shown in Figure 1b. Figure 1c,d show the gene expression details of endodermal differentiation as well as the gene expression of both the proximal and distal populations of lung epithelial cells after completing the differentiation.

<table><tbody><tr><td>&lt;strong&gt;Cell Culture&lt;/strong&gt;</td><td></td><td></td><td></td></tr><tr><td>12 well plates</td><td>Corning</td><td>3512</td><td></td></tr><tr><td>12-well inserts, 0.4um, translucent</td><td>VWR</td><td>10769-208</td><td></td></tr><tr><td>2-mercaptoethanol</td><td>Sigma-Aldrich</td><td>M3148</td><td></td></tr><tr><td>Accutase</td><td>Innovative Cell Tech</td><td>AT104</td><td></td></tr><tr><td>ascorbic acid</td><td>Sigma</td><td>A4544</td><td></td></tr><tr><td>B27 without retinoic acid</td><td>ThermoFisher</td><td>12587010</td><td></td></tr><tr><td>Bovine serum albumin (BSA) Fraction V, 7.5% solution</td><td>Gibco</td><td>15260-037</td><td></td></tr><tr><td>Dispase</td><td>StemCellTech</td><td>7913</td><td></td></tr><tr><td>DMEM/F12</td><td>Gibco</td><td>10565042</td><td></td></tr><tr><td>FBS</td><td>Gibco</td><td>10082139</td><td></td></tr><tr><td>Glutamax</td><td>Life Technologies</td><td>35050061</td><td></td></tr><tr><td>Ham&amp;rsquo;s F12</td><td>Invitrogen</td><td>11765-054</td><td></td></tr><tr><td>HEPES</td><td>Gibco</td><td>15630-080</td><td></td></tr><tr><td>Iscove&amp;rsquo;s Modified Dulbecco&amp;rsquo;s Medium (IMDM) + Glutamax</td><td>Invitrogen</td><td>31980030</td><td></td></tr><tr><td>Knockout Serum Replacement (KSR)</td><td>Life Technologies</td><td>10828028</td><td></td></tr><tr><td>Matrigel</td><td>Corning</td><td>354230</td><td></td></tr><tr><td>Monothioglycerol</td><td>Sigma</td><td>M6145</td><td></td></tr><tr><td>mTeSR plus Kit (10/case)</td><td>Stem Cell Tech</td><td>5825</td><td></td></tr><tr><td>N2</td><td>ThermoFisher</td><td>17502048</td><td></td></tr><tr><td>NEAA</td><td>Life Technologies</td><td>11140050</td><td></td></tr><tr><td>Pen/strep</td><td>Lonza</td><td>17-602F</td><td></td></tr><tr><td>ReleSR</td><td>Stem Cell Tech</td><td>5872</td><td></td></tr><tr><td>RPMI1640 + Glutamax</td><td>Life Technologies</td><td>12633012</td><td></td></tr><tr><td>TrypLE</td><td>Gibco</td><td>12605-028</td><td></td></tr><tr><td>Y-27632 (Rock Inhibitor)</td><td>R&amp;amp;D Systems</td><td>1254/1</td><td></td></tr><tr><td>&lt;strong&gt;Growth Factors/Small Molecules&lt;/strong&gt;</td><td></td><td></td><td></td></tr><tr><td>Activin A</td><td>R&amp;amp;D Systems</td><td>338-AC</td><td></td></tr><tr><td>All-trans retinoic acid (RA)</td><td>Sigma-Aldrich</td><td>R2625</td><td></td></tr><tr><td>BMP4</td><td>R&amp;amp;D Systems</td><td>314-BP/CF</td><td></td></tr><tr><td>Br-cAMP</td><td>Sigma-Aldrich</td><td>B5386</td><td></td></tr><tr><td>CHIR99021</td><td>Abcam</td><td>ab120890</td><td></td></tr><tr><td>Dexamethasone</td><td>Sigma-Aldrich</td><td>D4902</td><td></td></tr><tr><td>Dorsomorphin</td><td>R&amp;amp;D Systems</td><td>3093</td><td></td></tr><tr><td>EGF</td><td>R&amp;amp;D Systems</td><td>236-EG</td><td></td></tr><tr><td>FGF10</td><td>R&amp;amp;D Systems</td><td>345-FG/CF</td><td></td></tr><tr><td>FGF7</td><td>R&amp;amp;D Systems</td><td>251-KG/CF</td><td></td></tr><tr><td>IBMX (3-Isobtyl-1-methylxanthine)</td><td>Sigma-Aldrich</td><td>I5879</td><td></td></tr><tr><td>SB431542</td><td>R&amp;amp;D Systems</td><td>1614</td><td></td></tr><tr><td>VEGF/PIGF</td><td>R&amp;amp;D Systems</td><td>297-VP/CF</td><td></td></tr><tr><td>&lt;strong&gt;Primary antibodies&lt;/strong&gt;</td><td></td><td></td><td>&lt;strong&gt;Dilution rate&lt;/strong&gt;</td></tr><tr><td>CXCR4-PE</td><td>R&amp;amp;D Systems</td><td>FAB170P</td><td>1:200 (F)</td></tr><tr><td>HOPX</td><td>Santa Cruz Biotech</td><td>sc-398703</td><td>0.180555556</td></tr><tr><td>HTII-280</td><td>Terrace Biotech</td><td>TB-27AHT2-280</td><td>0.145833333</td></tr><tr><td>KRT5</td><td>Abcam</td><td>ab52635</td><td>0.180555556</td></tr><tr><td>NKX2-1</td><td>Abcam</td><td>ab76013</td><td>0.25</td></tr><tr><td>NKX2-1-APC</td><td>LS-BIO</td><td>LS-C264437</td><td>1:1000 (F)</td></tr><tr><td>proSPC</td><td>Abcam</td><td>ab40871</td><td>0.215277778</td></tr><tr><td>SCGB3A2</td><td>Abcam</td><td>ab181853</td><td>0.25</td></tr><tr><td>SOX2</td><td>Invitrogen</td><td>MA1-014</td><td>0.180555556</td></tr><tr><td>SOX9</td><td>R&amp;amp;D Systems</td><td>AF3075</td><td>0.180555556</td></tr><tr><td>SPB (mature)</td><td>7 Hills</td><td>48604</td><td>1: 1500 (F) 1:500 (W)&lt;sup&gt;a&lt;/sup&gt;</td></tr><tr><td>SPC (mature)</td><td>LS Bio</td><td>LS-B9161</td><td>1:100 (F); 1:500 (W)&lt;sup&gt; a&lt;/sup&gt;</td></tr></tbody></table>

generation of 3d whole lung organoids from induced pluripotent stem cells for modeling lung developmental biology and disease

Generation of 3D Whole Lung Organoids from Induced Pluripotent Stem Cells for Modeling Lung Developmental Biology and Disease

Human lung development and disease has been difficult to study due to the lack of biologically relevant in vitro model systems. Human induced pluripotent stem cells (hiPSCs) can be differentiated stepwise into 3D multicellular lung organoids, made of both epithelial and mesenchymal cell populations. We recapitulate embryonic developmental cues by temporally introducing a variety of growth factors and small molecules to efficiently generate definitive endoderm, anterior foregut endoderm, and subsequently lung progenitor cells. These cells are then embedded in growth factor reduced (GFR)-basement membrane matrix medium, allowing them to spontaneously develop into 3D lung organoids in response to external growth factors. These whole lung organoids (WLO) undergo early lung developmental stages including branching morphogenesis and maturation after exposure to dexamethasone, cyclic AMP and isobutylxanthine. WLOs possess airway epithelial cells expressing the markers KRT5 (basal), SCGB3A2 (club) and MUC5AC (goblet) as well as alveolar epithelial cells expressing HOPX (alveolar type I) and SP-C (alveolar type II). Mesenchymal cells are also present, including smooth muscle actin (SMA), and platelet-derived growth factor receptor A (PDGFR&#945;). iPSC derived WLOs can be maintained in 3D culture conditions for many months and can be sorted for surface markers to purify a specific cell population. iPSC derived WLOs can also be utilized to study human lung development, including signaling between the lung epithelium and mesenchyme, to model genetic mutations on human lung cell function and development, and to determine the cytotoxicity of infective agents.

24 hours after plating, day 1, iPSCs should be 50%-90% confluent. On day 2, DE should be 90%-95% confluent. During DE induction, it is common to observe significant cell death on day 4 but attached cells will retain a compact cobblestone morphology (Figure 2b). Discontinue differentiation if the majority of adherent cells detach and consider shortening exposure to DE media with activin A by 6-12 h. During AFE induction, cell death is minimal, and cells remain adherent, but will appear smalle...

The article describes step wise directed differentiation of induced pluripotent stem cells to three-dimensional whole lung organoids containing both proximal and distal epithelial lung cells along with mesenchyme.

Human lung development and disease has been difficult to study due to the lack of biologically relevant in vitro model systems. Human induced pluripotent ...

generation-3d-whole-lung-organoids-from-induced-pluripotent-stem

Research

JoVE Journal

Developmental Biology

This protocol efficiently directs mouse embryonic stem cell-derived definitive endoderm to mature airway epithelial cells. This differentiation technique uses 3-dimensional decellularized lung scaffolds to direct lung lineage specification, in a defined, serum-free culture setting.

Generation of ESC-derived Mouse Airway Epithelial Cells Using Decellularized Lung Scaffolds

Here, we present a protocol for the preparation of agarose-filled human precision-cut lung slices from resected patient tissue that are suitable for generating 3D lung tissue cultures to model human lung diseases in biological and biomedical studies.

Generation of Human 3D Lung Tissue Cultures (3D-LTCs) for Disease Modeling

This protocol allows for the differentiation of human pluripotent cells into intestinal organoids. The protocol mimics normal human development by differentiating cells into a population of definitive endoderm, hindgut endoderm and then intestinal epithelium. This makes the protocol suitable for studying both intestinal development as well as disease modelling applications.

Generation of hiPSC-Derived Intestinal Organoids for Developmental and Disease Modelling Applications

This article provides a detailed methodology for tissue dissociation and cellular fractionation approaches allowing enrichment of viable epithelial cells from proximal and distal regions of the human lung. Herein these approaches are applied for the functional analysis of lung epithelial progenitor cells through the use of 3D organoids culture models.

Isolation and Enrichment of Human Lung Epithelial Progenitor Cells for Organoid Culture

Here, we describe a protocol to create developmentally relevant human heart organoids (hHOs) efficiently using human pluripotent stem cells by self-organization. The protocol relies on the sequential activation of developmental cues and produces highly complex, functionally relevant human heart tissues.

Generating Self-Assembling Human Heart Organoids Derived from Pluripotent Stem Cells

The protocol presents a method to derive human lung organoids from primary lung tissues, expand the lung organoids and induce proximal differentiation to generate 3D and 2D airway organoids that faithfully phenocopy the human airway epithelium.

Establishing Human Lung Organoids and Proximal Differentiation to Generate Mature Airway Organoids

This protocol describes the key steps to generate and characterize murine oral-esophageal 3D organoids that represent normal, preneoplastic, and squamous cell carcinoma lesions induced via chemical carcinogenesis.

Modeling Oral-Esophageal Squamous Cell Carcinoma in 3D Organoids

This protocol presents a method for generating vascular organoids using human pluripotent stem cells.

Vascular Organoid Generation from Human-Induced Pluripotent Stem Cells

Here we describe a protocol for generating human induced-pluripotent stem cells from patient-derived fibroblast-like synoviocytes, using a lentiviral system without feeder cells.

Generation of Induced-pluripotent Stem Cells Using Fibroblast-like Synoviocytes Isolated from Joints of Rheumatoid Arthritis Patients

The goal of this protocol is to show the protocol for reprogramming melanoma tumor-infiltrating lymphocytes into induced pluripotent stem cells.

Generation of Induced Pluripotent Stem Cells from Human Melanoma Tumor-infiltrating Lymphocytes

Learn to generate 3D lung organoids from hiPSCs using stepwise differentiation and matrix embedding techniques. This method enables modeling of human lung development and disease in vitro.

Generation of 3D Whole Lung Organoids from Induced Pluripotent Stem Cells for Modeling Lung Developmental Biology and Disease

Explore More Videos